PALI

MKT CAP:$368M

Palisade Bio Inc

Market Cap

$368M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.03-$0.47 (-18.80%)

Jul 15, 2026

52W High $2.8052W Low $0.54

Company Details

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product...

Leadership

J. D. Finley

CEO, CFO & Director

Mitchell Lawrence Jones M.D., Ph.D.

President & Chief Medical Officer

Ramesh C. Donthamsetty

Head of Corporate Development & Investor Relations

Joerg Heyer Ph.D.

Head of Translational Science & Medicine

James Izanec M.D.

VP & Head of Clinical Development

Daniel J. Larkins

Head of Global Regulatory Affairs

Adarsh Patel M.B.A., M.S.

Head of Chemistry, Manufacturing & Controls

Dawn Louro

VP & Head of Clinical Operations

Ryker Willie

Senior VP of Finance & Corporate Controller

IPO Date

Dec 20, 2006

Website

www.palisadebio.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$24M

EPS (Diluted)

Free Cash Flow

-$12M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee